Published in Thyroid on April 01, 2009
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2006) 12.23
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology (2005) 4.96
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid (2006) 3.03
Subcellular-resolution molecular imaging within living tissue by fiber microendoscopy. Opt Express (2007) 3.01
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab (2010) 2.74
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol (2006) 2.68
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2012) 2.14
Multispectral optical imaging device for in vivo detection of oral neoplasia. J Biomed Opt (2008) 2.03
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid (2005) 1.89
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res (2007) 1.80
Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol (2007) 1.77
Noninvasive imaging of oral neoplasia with a high-resolution fiber-optic microendoscope. Head Neck (2011) 1.77
Nano-bio-chip sensor platform for examination of oral exfoliative cytology. Cancer Prev Res (Phila) (2010) 1.76
Autofluorescence and diffuse reflectance spectroscopy of oral epithelial tissue using a depth-sensitive fiber-optic probe. Appl Opt (2008) 1.68
Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol (2013) 1.68
Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging (2003) 1.68
Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila) (2009) 1.66
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg (2003) 1.64
Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology (2009) 1.62
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol (2007) 1.61
The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab (2011) 1.60
Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery (2003) 1.60
BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res (2004) 1.58
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab (2007) 1.53
Human tracheal reconstruction with a composite radial forearm free flap and prosthesis. Ann Thorac Surg (2006) 1.46
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab (2006) 1.45
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid (2013) 1.45
Cervista HPV assays for fine-needle aspiration specimens are a valid option for human papillomavirus testing in patients with oropharyngeal carcinoma. Cancer Cytopathol (2013) 1.43
Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer (2004) 1.43
Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression. Surgery (2002) 1.42
Recurrence after treatment of micropapillary thyroid cancer. Thyroid (2009) 1.41
Accuracy of in vivo multimodal optical imaging for detection of oral neoplasia. Cancer Prev Res (Phila) (2012) 1.33
In vivo imaging of oral neoplasia using a miniaturized fiber optic confocal reflectance microscope. Oral Oncol (2008) 1.32
A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem (2006) 1.31
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q (2006) 1.30
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res (2004) 1.30
High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res (2009) 1.29
Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience. Cancer (2007) 1.29
CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior. Genes Chromosomes Cancer (2007) 1.29
Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope (2005) 1.27
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab (2010) 1.26
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res (2004) 1.26
Elective and therapeutic selective neck dissection. Oral Oncol (2005) 1.26
Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid (2009) 1.25
Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys (2008) 1.23
Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer (2003) 1.22
Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck (2009) 1.21
Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer (2007) 1.21
Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J Invest Dermatol (2007) 1.19
An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg (2008) 1.19
Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck (2009) 1.17
Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg (2003) 1.16
Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2003) 1.15
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab (2008) 1.14
p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res (2003) 1.13
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab (2009) 1.13
Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res (2004) 1.13
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid (2013) 1.12
Four patients with cutaneous metastases from medullary thyroid cancer. Thyroid (2008) 1.12
Epithelioid hemangioendothelioma of the head and neck: role of podoplanin in the differential diagnosis. Head Neck Pathol (2007) 1.10
Recent advances in thyroid cancer. Curr Probl Surg (2008) 1.09
The impact of palliative care consultation on symptom assessment, communication needs, and palliative interventions in pediatric patients with cancer. J Palliat Med (2009) 1.09
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab (2015) 1.08
MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther (2010) 1.08
A prospective study of intraoperative lymphatic mapping for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg (2002) 1.08
Parathyroid carcinoma: a 22-year experience. Head Neck (2004) 1.08
DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res (2011) 1.08
Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol (2006) 1.08
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab (2012) 1.06
Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res (2006) 1.06
Multimodal snapshot spectral imaging for oral cancer diagnostics: a pilot study. Biomed Opt Express (2013) 1.05
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res (2009) 1.04
A fiber-optic fluorescence microscope using a consumer-grade digital camera for in vivo cellular imaging. PLoS One (2010) 1.04
Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid (2010) 1.04
Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res (2010) 1.02
Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics. Clin Cancer Res (2010) 1.02